BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: BMS is a global pharmaceutical and healthcare company organized into three segments: Pharmaceuticals, Nutritionals, and Other Health Care. The reporting period is heavily influenced by the ongoing patent litigation regarding its top-selling product, PLAVIX*, and the residual impact of generic competition.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 4% year-over-year. U.S. sales dropped 5% primarily due to the loss of exclusivity for PRAVACHOL and lower PLAVIX* sales caused by residual generic inventory. International sales remained flat.
• Profitability: Earnings before minority interest and income taxes fell 23% to $917 million. This was driven by lower sales and higher restructuring charges ($37 million vs. $1 million in 2006), partially offset by a significantly lower effective tax rate.
• Tax Benefit: The effective tax rate dropped to 9.4% from 27.5% due to a $105 million tax benefit from the favorable resolution of IRS matters regarding litigation settlement deductibility and foreign tax credits.
• Cash Flow Improvement: Operating cash flow surged to $765 million from $83 million, driven by favorable changes in working capital (specifically accounts payable and accrued expenses) and the absence of large litigation settlement payments seen in the prior year.
• Product Performance:
  • PLAVIX*: Sales declined 5% ($938M) due to generic competition; estimated adverse impact was $300M-$350M.
  • PRAVACHOL: Sales plummeted 75% ($135M) following loss of market exclusivity.
  • Growth Drivers: ABILIFY* (+29%), REYATAZ (+27%), and SUSTIVA Franchise (+29%) showed strong growth.

Guidance, Outlook, and Risks

• PLAVIX* Litigation: The trial regarding patent infringement by Apotex concluded in February 2007; the company is awaiting the court's decision. A loss would result in renewed generic competition, which management states would be material to sales and cash flows.
• DOJ Agreement: On May 10, 2007, BMS reached an agreement in principle with the DOJ Antitrust Division to plead guilty to two violations of Section 1001 (false statements) regarding the PLAVIX* settlement negotiations. The maximum fine is $1 million. This plea is expected to allow the termination of the existing Deferred Prosecution Agreement (DPA).
• 2007 Outlook:
  • Expected net sales reductions from exclusivity losses to moderate to $900M-$1.0 billion (down from $1.4B in 2006).
  • PLAVIX* sales and earnings growth expected in 2007, assuming no renewed generic competition.
  • Gross margin expected to improve due to higher-margin product mix and manufacturing efficiencies.
• Legal Reserves: The company has recorded $499 million in reserves for a civil settlement regarding drug pricing and marketing practices investigations.
• Strategic Alliances: In April 2007, BMS entered a collaboration with Pfizer for apixaban (anticoagulant), receiving a $250 million upfront payment.

Investor Verification Checklist

• PLAVIX* Patent Ruling: Monitor the outcome of the Apotex patent infringement trial, as a loss would materially impact future revenue.
• DOJ Plea Finalization: Verify the finalization of the guilty plea agreement with the DOJ and the subsequent termination of the Deferred Prosecution Agreement.
• Generic Inventory Depletion: Track the depletion of generic clopidogrel inventory in distribution channels to assess the timeline for PLAVIX* sales recovery.
• Exclusivity Losses: Confirm the trajectory of sales declines for PRAVACHOL and other products losing patent protection against the $900M-$1.0B guidance range.
• Legal Settlements: Review the status of the $499 million pricing/marketing settlement and the $1 million DOJ fine to ensure no additional liabilities arise.